



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



A clinical trial to assess the role of repetitive Transcranial Magnetic Stimulation (rTMS) in Smoking Cessation in an Egyptian Sample

Thesis

Submitted for the partial fulfilment of the Doctoral degree in Psychiatry

By

Mayar Medhat Nawara MohyiELDin Nawara

M.B.B.Ch., M.Sc. Neuropsychiatry

Under the Supervision of

Professor Gihan Medhat ELNahas

Professor of Psychiatry

Faculty of Medicine, Ain Shams University

Professor Menan Abdelmaksoud Rabie

Professor of Psychiatry

Faculty of Medicine, Ain Shams University

Professor Mahmoud Mamdouh ElHabiby

Professor of Psychiatry

Faculty of Medicine, Ain Shams University

Assistant Professor Hussien Ahmed Elkholy

Assistant Professor of Psychiatry

Faculty of Medicine, Ain Shams University

**Assistant Professor Mohamed Hossam Eldin
Abdelmoneam**

Assistant Professor of Psychiatry

Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2021

Acknowledgements

No words can express my gratitude towards **Professor Gihan Medhat ELNahas**. This work could not have been accomplished without her guidance, patience or tolerance. Dearest Professor, thank you for believing in me.

My dear **Professor Menan Abdelmaksoud Rabie** is a role model in cooperation and versatility. I thank her for giving me a part of her time to oversee the production of this work.

I have been a disciple of **Professor Mahmoud Mamdouh ElHabiby** since I treaded my first steps in the department of Neuropsychiatry. I owe him, not only for the production of this work, but for the influence I have had to become a better physician and academic.

Assistant Professor Hussien Ahmed Elkholy worked with me on this thesis in maybe three different continents. He has made sure, regardless the circumstances to set aside part of his time to meet for guidance on my work.

Assistant Professor Mohamed Hossam Eldin Abdelmoneam has been very supportive throughout the production of this work, both academically and psychologically. He has had enough humor and patience to accompany through the process with the least damage.

A note of special gratitude goes to **Dr. Dina Ahmed, Dr. Habiba Abozeid and Dr. Asmaa Hussein** for assistance with the field work. Their presence has been vital for the blinding procedures in this study.

2021 Acknowledgements

Last but not least, I owe a great thanks to the participants who volunteered and the colleagues who spread the word for the recruitment in this study. Without those people, we could not advance in science.

Contents

Acknowledgements	2
Contents	4
List of Abbreviations	5
List of Tables	9
List of Figures	10
Introduction.....	11
Aims and objectives.....	15
Review of Literature	16
Chapter 1 Tobacco Addiction	16
Chapter 2 Treating Tobacco Addiction.....	48
Chapter 3 Repetitive Transcranial Magnetic Stimulation (rTMS) and The Treatment of Tobacco Addiction.....	75
Subjects and methods.....	101
Results.....	123
Discussion	150
Conclusion and recommendations	163
Summary	165
References.....	170
Appendix (1) Fagerstrom Test for Nicotine Dependence.....	177
Appendix (2) Lebanese Waterepipe Dependence Scale-11	178
Appendix (3) Arabic Tobacco Craving Questionnaire-12.....	179
Appendix (4) Nicotine Use Inventory.....	181
الملخص.....	182

List of Abbreviations

5 As	Ask-Advise-Assess-Assist-Arrange
AAC	Ask-Advise-Connect
AAR	Ask-Advice-Refer
ACC	Anterior Cingulate Cortex
Ach	Acetyl Choline
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
ANOVA	Analysis of variance
AP	Action Potential
APA	American Psychiatric Association
APB	Abductor Pollicis Brevis
app	Application
ATCQ-12	Arabic Tobacco Craving Questionnaire
BCE	Before the Current Era
BDNF	Brain-Derived Neurotrophic Factor
BEN	Brain Entropy
Ca ²⁺	Calcium ion
cAMP	Cyclic Adenosine Monophosphate
CBF	Cerebral Blood Flow
CBT	Cognitive behavioral therapy
CI	Confidence Interval
CNDS	Competing Neurobehavioral Decision System
CO	Carbon Monoxide
COHb	Carboxyhemoglobin
COPD	Chronic Obstructive Pulmonary Disease
CPD	Cigarettes Per Day
CQR	Continuous Quit Rate
DA	Dopamine
DLPFC	Dorsolateral Prefrontal Cortex
D-mechanism	Direct mechanism
DSM-5	Diagnostic and Statistical Manual of mental disorders (5th edition)
DSM-IV	Diagnostic and Statistical Manual (4th edition)
DTMS	Deep Transcranial Magnetic Stimulation
EEG	Electroencephalography

List of Abbreviations

E-field	Electric field
ENDS	Electronic nicotine delivery systems
FDA	Food and Drug Administration
fMRI	Functional Magnetic Resonance Imaging
FTND	Fagerstrom Test For Nicotine Dependence
GABA	Gamma Amino Butyric Acid
Glu	Glutamate
Gs	G=protein coupled stimulatory receptor
h	hour
HB-IPN	habenula–interpeduncular system
HF	High frequency
Hx	History
Hz	Hertz
ICD-10	International Classification of Diseases (10th revision)
ICH	International Council on Harmonization
I-mechanism	Indirect mechanism
IOMS	Islamic Organization for Medical Sciences
IPN	Interpeduncular Nucleus
K+	Potassium ion
Ka	Acid dissociation constant
kA	kilo Ampere
LDTg	laterodorsal tegmental nucleus
LF	Low Frequency
LTD	Long-term Depression
LTP	Long-term Potentiation
LWDS-11	Japanese Waterpipe Dependence Scale
M1	Primary Motor Area
MAO	Monoamine oxidase
MDD	Major Depressive Disorder
MEP	Motor Endplate Potential
Mg ²⁺	Magnesium ion
MHb	Medial Habenula
MINI	Mini International Neuropsychiatric Interview
MPFC	Medial Prefrontal cortex
MRI	Magnetic Resonance Imaging
ms	millisecond

List of Abbreviations

MT	Motor Threshold
MTP	Motor Threshold Potential
N	number
Na ⁺	Sodium ion
NAc	Nucleus Accumbens
nAChR	nicotinic Acetyl Choline Receptor
NCD	Non-communicable diseases
NCI	National Cancer Institute
NIBS	Non-invasive Brain Stimulation
NMDAR	N-methyl D-aspartate receptors
NO	Nitric Oxide ¹
NRT	Nicotine Replacement Therapy
NUI	Nicotine Use Inventory
OCD	Obsessive Compulsive Disorder
OFC	Orbitofrontal cortex
OR	Odds Ratio
PFC	Prefrontal Cortex
PKA	Protein Kinase A
pKa	pH acid dissociation constant
ppm	Parts Per Million
PPTg	pedunculopontine tegmental nucleus
ppTMS	Paired-pulse Transcranial Magnetic Stimulation
QPS	Quadripulse Stimulation
REC	Research Ethics Committee
rMT	Resting Motor Threshold
rppTMS	repetitive paired pulse Transcranial Magnetic Stimulation
RR	Relative Risk
rTMS	repetitive Transcranial Magnetic Stimulation
SFG	Superior Frontal Gyrus
SMFC	Superomedial Frontal Cortex
SN	Spiny Neurons
SNpc	substantia nigra pars compacta
SPSS	Statistical Package for the Social Sciences
spTMS	Single Pulse Transcranial Magnetic Stimulation
sTCQ	Short form of Tobacco Craving Questionnaire
SUD	Substance Use Disorder
TBS	Theta Burst Stimulation

List of Abbreviations

tDCS	Transcranial Direct Current Stimulation
TMS	Transcranial Magnetic Stimulation
TQD	Target Quit Date
Trk-B	Tropomyosin Receptor Kinase B
U.S.	United States
VTA	Ventral Tegmental Area
WHO	World Health Organization

List of Tables

TABLE 1 DIVERSITY OF TOBACCO PRODUCTS ADAPTED FROM (PROCHASKA & BENOWITZ, 2019)	25
TABLE 2 ADAPTED FROM TREATING TOBACCO USE AND DEPENDENCE: 2008 UPDATE (FIORE ET AL.)	111
TABLE 3 PARTICIPANT CHARACTERISTICS	124
TABLE 4 SMOKING PROFILE AMONG SAMPLE	126
TABLE 5 BASELINE SMOKING PARAMETERS	127
TABLE 6 BASELINE CRAVING PARAMETERS	128
TABLE 7 CONTINUOUS ABSTINENCE 12 WEEKS POST TREATMENT	130
TABLE 8 CONTINUOUS ABSTINENCE AT END OF TRIAL	130
TABLE 9 POINT PREVALENCE ABSTINENCE OVER TIME IN STUDY GROUP	132
TABLE 10 POINT PREVALENCE ABSTINENCE OVER TIME IN CONTROL GROUP	132
TABLE 11 NUMBER OF DAYS SMOKED DURING TRIAL	135
TABLE 12 COMPARISON OF CARBON MONOXIDE READING AT BASELINE AND END OF TREATMENT SESSIONS	136
TABLE 13 COMPARISON OF CIGARETTE CONSUMPTION AT BASELINE AND END OF FOLLOW-UP PERIOD	137
TABLE 14 TREATMENT RESPONSE	138
TABLE 15 PRETREATMENT LEVEL OF DEPENDENCE (FTND) WITH CIGARETTE CONSUMPTION	139
TABLE 16 NUMBER OF PACK YEARS WITH CIGARETTE CONSUMPTION DURING THE TRIAL	140
TABLE 17 BASELINE CRAVING PARAMETERS WITH CONTINUOUS ABSTINENCE AT THE END OF THE TRIAL	141
TABLE 18 BASELINE CRAVING PARAMETERS WITH CIGARETTE CONSUMPTION AT THE END OF THE TRIAL	142
TABLE 19 TREATMENT RESPONSE WITH BASELINE LEVEL OF DEPENDENCE, PACK YEARS AND CRAVING PARAMETERS	143
TABLE 20 TREATMENT RESPONSE AND BASELINE PARAMETERS IN STUDY GROUP	144

List of Figures

FIGURE 1 THE CIRCUITRY OF NICOTINE ADDICTION	28
FIGURE 2 TRIAL TIMELINE	109
FIGURE 3 STUDY FLOW DIAGRAM	119
FIGURE 4 CARBON MONOXIDE AT BASELINE AND END OF TRIAL	136
FIGURE 5 CIGARETTE CONSUMPTION AT BASELINE AND END OF TRIAL	137
FIGURE 6 REPEATED MEASURES OF ATCQ-12 EMOTIONALITY OVER TIME	145
FIGURE 7 REPEATED MEASURES OF ATCQ-12 EXPECTANCY OVER TIME	147
FIGURE 8 REPEATED MEASURES OF ATCQ-12 COMPULSIVITY OVER TIME	148
FIGURE 9 REPEATED MEASURES OF ATCQ-12 PURPOSEFULNESS OVER TIME	149

Introduction

Background

The World Health Organization (WHO) reported that tobacco use continues to be the leading global cause of preventable death with almost 6 million deaths each year (World Health Organization, 2019). Although the prevalence is declining worldwide, it still seems to be increasing in the Eastern Mediterranean region. Despite the well-documented morbidity and mortality, estimated prevalence of smoking any tobacco product among males aged ≥ 15 years in Egypt has been rising from 43.9% in 2010 to 49.9% in 2015 and is predicted to continue rising until 2025 (World Health Organization, n.d.).

Research indicates that most smokers endorse a desire to quit, but few (only about 4–7%) will actually quit in a given year without treatment. A striking discrepancy exists between early success rates and long-term outcomes. In most studies, more than 50% of smokers achieve abstinence for at least a few initial weeks. Of initially successful quitters, 50% to 60% go on to relapse within a year (Tonstad et al., 2006). Currently used medications for tobacco dependence include nicotine replacement therapy, varenicline HCl, bupropion HCl, and group and/or individual psychotherapy. These treatments show around 20–25% abstinence rates in smokers at 6 months or more after treatment

initiation and are therefore considerably better than attempting abstinence without treatment. Research also shows that a high percentage of smokers who initiate treatment will relapse within the first year (Brody & Cook, 2011).

The major addictive component of tobacco, Nicotine, activates the mesolimbic dopamine system originating in the ventral tegmental area and projecting to reward-related brain areas including the prefrontal cortex (PFC), nucleus accumbens (NAc), amygdala and hippocampus (Di Chiara, 2000). A decreased activity of the brain reward system during nicotine withdrawal has been shown to be closely associated with craving, relapse and continued nicotine consumption (Epping-jordan et al., 1998). Additional support for this hypothesis comes from studies with the atypical antidepressant bupropion that blocks neuronal uptake of dopamine which is currently approved as a treatment for smoking cessation (Holm & Spencer, 2000). For these reasons, modulation of dopaminergic neurotransmission might serve as a potential target for treating tobacco addiction.

Repetitive transcranial magnetic stimulation (rTMS) is a tool that can potentially induce dopamine release and long-lasting changes in neural excitability (Dinur-Klein et al., 2014). High frequency rTMS at the left dorsolateral prefrontal cortex (LDPFC) has been shown to modulate cigarette cue-induced